Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx, Inc. reports developments in precision medicine for transplant patients and caregivers. The company’s updates center on non-invasive molecular testing for heart, kidney, and lung transplantation, including AlloSure, AlloMap, HeartCare, and related evidence generation for post-transplant surveillance, risk assessment, and longitudinal patient management.
CareDx news also covers operating and financial results for testing services and patient and digital solutions, product and platform launches such as VANTx clinical data analytics, clinical conference presentations, material agreements, and Nasdaq-related governance matters including inducement equity awards.
CareDx (Nasdaq: CDNA), described as The Transplant Company and a leading precision medicine company for transplant patients, will join two investor events in June 2026.
Management will present at Jefferies and Goldman Sachs healthcare conferences, with live and archived webcasts on the CareDx investor relations site.
CareDx (Nasdaq: CDNA) announced that a 2021 qui tam action against the company has been dismissed by the U.S. District Court for the Eastern District of New York as of April 23, 2026, with no monetary payment required.
The dismissal follows the plaintiff’s request and Department of Justice concurrence. The case, filed February 12, 2021, led to a DOJ investigation that, according to CareDx, concluded on October 8, 2024 without any finding of wrongdoing. CareDx has consistently denied allegations of wrongdoing.
CareDx (Nasdaq: CDNA) announced inducement restricted stock unit (RSU) awards granted April 30, 2026, to 23 newly hired employees totaling 63,856 RSUs under the company’s 2019 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over four years: 25% at the first anniversary of each employee’s vesting commencement date and then 1/16th quarterly, subject to continued service through each vesting date.
CareDx (Nasdaq: CDNA) agreed to acquire Naveris, a commercial-stage precision oncology diagnostics company, for $160 million up-front plus up to $100 million in revenue-based earnouts. The Naveris TTMV® liquid biopsy is Medicare-reimbursed and reported $34 million revenue in 2025.
CareDx expects Naveris revenue to grow 30–40% annually over three years, reported Q1 2026 unaudited revenue of ~$12 million, 65% gross margin, and a Q1 net operating loss of $0.2 million. Transaction expected to close in Q3 2026 and is forecasted to be neutral to CareDx's FY2026 adjusted EBITDA guidance.
CareDx (Nasdaq: CDNA) reported Q1 2026 revenue of $118M, up 39% year-over-year, driven by Testing Services of $91M (+48%) and volumes ~54,900 (+17%). GAAP net income was $3M; adjusted EBITDA was $19M. Company raised 2026 revenue guidance to $447M–$465M and adjusted EBITDA to $43M–$57M, announced a $170M lab-products divestiture agreement and a $100M share repurchase authorization.
CareDx (Nasdaq: CDNA) will present 50 abstracts, 16 oral presentations and two symposia at ISHLT 2026 (April 22–25) featuring data from 95 transplant centers. Key findings from SHORE (≈2,700 heart transplant patients) and ALAMO support non-invasive HeartCare and AlloSure Lung for early injury detection, longitudinal risk assessment, and surveillance cost comparisons.
CareDx also described MERIT, a randomized trial testing management guided by dual-positive molecular results in heart transplant recipients.
CareDx (Nasdaq: CDNA) introduced AlloSeq Nano, a nanopore long‑read HLA and ABO genotyping assay delivering high‑resolution results in under three hours and about 45 minutes hands‑on for eleven HLA loci plus ABO.
The company is showcasing AlloSeq Nano at EFI 2026 on April 23 and announced a definitive agreement to divest its Lab Products business to EuroBio Scientific, expected to close by the end of Q3 2026.
CareDx (Nasdaq: CDNA) agreed to sell its Lab Products business to EuroBio Scientific for $170 million, aiming to sharpen focus on Precision Medicine Testing Services and Patient and Digital Solutions.
Key terms include a perpetual North America distribution right for post-transplant IVD tests including AlloSeq cfDNA, expected close by end of Q3 2026 pending Swedish regulatory review, and at least six months of transition services. Preliminary Q1 2026 results: $118M revenue (+39% YoY), Testing Services revenue $91M (+48% YoY), testing volume ~54,900 (+17% YoY), Patient and Digital $16M (+33%), Lab Products $10M (-4%), and cash ~$198M as of March 31, 2026.
CareDx (Nasdaq: CDNA) will report first quarter 2026 financial results after market close on April 28, 2026. The company will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET that day.
A live and archived webcast will be available on the Events & Presentations section of CareDx's Investor Relations website; telephone participants must register to receive a dial-in number and PIN.
CareDx (Nasdaq: CDNA) launched VANTx, an AI‑powered, cloud‑native clinical data and analytics platform announced March 5, 2026. VANTx ingests real‑time, de‑identified molecular and clinical data, runs on Databricks with the Llama 3 foundational model, and supports cohort analysis, research, and real‑world evidence generation.
Available now via medical affairs consultation, CareDx plans self‑service, permissioned clinician access later in 2026.